Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 3/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.63 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.63 |
| ▸ | SLC22A12 | Q96S37 | 16/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.56 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.56 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.54 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31700423 | 0.84 | PTPN2 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL31700420 | 0.81 | PTPN1 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL31702050 | 0.81 | PTPN1 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL31701729 | 0.81 | PTPN2 (0.61) | PTPN2PTPN1PTPN5SLC22A12 | |
| SCHEMBL31702046 | 0.81 | PTPN2 (0.61) | PTPN2PTPN1PTPN5SLC22A12CYP2C9 | |
| SCHEMBL31700372 | 0.81 | PTPN1 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL31700422 | 0.79 | PTPN2 (0.63) | PTPN2PTPN1PTPN5SLC22A12HSPD1 | |
| SCHEMBL31701128 | 0.79 | PTPN2 (0.64) | PTPN2PTPN1PTPN5SLC22A12HSPD1 | |
| SCHEMBL31700369 | 0.79 | NPC1 (0.55) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL31701732 | 0.78 | PTPN2 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | PTPN2 2771/4885PTPN1 3070/4885PTPN5 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.